News
Article
Author(s):
Afami-cel had engineered t-cell receptor T-cells target MAGE-A4+ tumors, which are highly expressed in synovial sarcoma with HLA-A*02.
The FDA accepted a biologics license application (BLA) for priority review for afamitresgene autoleucel (afami-cel; Adaptimmune Therapeutics plc), an investigational engineered T-cell therapy for the treatment of advanced synovial sarcoma, according to a press release. The application has a Prescription Drug User Fee Act target action date of August 4, 2024.1
Monkey Business - stock.adobe.com
Afami-cel has engineered t-cell receptor T-cells that target melanoma-associated antigen A4 positive (MAGE-A4+) tumors, which are highly expressed in synovial sarcoma with HLA-A*02.2
"Historic outcomes are poor for advanced synovial sarcoma, with low objective response rates for second-line therapies and overall survival of less than 12 months for [patients] who have received 2 or more prior lines of therapy. In clinical trials, afami-cel has demonstrated an impressive response rate of [approximately] 39% among heavily pre-treated patients with advanced synovial sarcoma and about a 17-month median survival. This regulatory milestone is a testament to our teams' relentless work to deliver a novel treatment option to more people diagnosed with synovial sarcoma,” Dennis Williams, PharmD, senior vice president of Late-Stage Development at Adaptimmune Therapeutics, said in the press release.1
The acceptance was supported by data from cohort 1 of the SPEARHEAD-1 trial, meeting its primary endpoint of efficacy.1
At the 2023 Connective Tissue Oncology Society annual meeting in Dublin, Ireland, positive data from the SPEARHEAD-1 trial were shared as an oral presentation. The trial was a phase 2, open-label study that included approximately 90 individuals with advanced synovial sarcoma or myxoid/round cell liposarcoma. Those who were included had an Eastern Cooperative Oncology Group performance status of 0 or 1; were HLA-A*02 positive with MAGE-A4 expression in ≥ 30% of tumor cells ≥ 2+ by immunohistochemistry; were 16 to 75 years of age; and received either an anthracycline- or ifosfamide-containing regimen.2
Trial Name: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
ClinicalTrial.gov ID: NCT04044768
Sponsor: Adaptimmune
Primary Completion Date: October 2021
Planned Completion Date: April 2038
Eligible individuals received a single dose of afami-cel after receiving lymphodepleting chemotherapy. Approximately 45 individuals were assigned to be in cohort 1 and 2, with cohort 1 evaluating the efficacy analysis and cohort 2 building on the efficacy and safety data and serving as sub-group analyses, according to a press release. Investigators found that cohort 2 had a response rate nearly identical to cohort 1, with cohort 3 being opened to include access to afami-cel ahead of commercialization.2
Individuals in the study were also heavily pretreated with a median of 3 prior lines of systemic therapy, ranging from 1 to 12. The outcomes showed that the historical control data after a single dose of afami-cel were favorable, according to the press release. Patients also had positive treatment-free intervals and the median time to next treatment was approximately 7 months overall and approximately 17 months for patients with a RECISTv1.1 response, according to the press release.2
The median overall survival (OS) was approximately 17 months overall, and those who responded to the drug were estimated to have a 70% chance of being alive 2 years after treatment. Higher afami-cel cellular persistence was also associated with a longer OS. Toxicities include cytokine release syndrome and reversible hematologic toxicities, which were consistent with previous findings.2
References
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
